Development stage healthcare delivery company HOPE Therapeutics Inc, a subsidiary of NRx Pharmaceuticals Inc (Nasdaq:NRXP), announced on Monday that it has appointed BTIG, a financial services company specialising in investment banking, institutional trading, research and related brokerage services, as its financial advisor.
The scope of the engagement includes advisory and assistance in evaluating strategic and financing options available to the company and identification, evaluation and negotiation of potential acquisition targets for the HOPE network of clinics, as well as equity and debt financing structures.
The company recently announced execution of an agreement for USD27m in funding for HOPE clinic acquisition. Upon closing of the first tranche of the anticipated financing, the company intends to leverage the investment with proposed bank debt and similar instruments to fund its initial rollup of Interventional Psychiatry Clinics.
Novartis' Fabhalta (iptacopan) receives US FDA approval
WuXi Biologics honoured for water security by CDP
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment
Niagen Bioscience secures US patent for nicotinamide riboside salt forms
Sobi forms research collaboration for development of Gamifant in sepsis
Black Diamond Therapeutics and Servier agree global licensing deal for BDTX-4933
Health Canada approves KEYTRUDA for advanced or recurrent endometrial carcinoma
Medivir secures European patent for fostrox and lenvatinib combination in liver cancer treatment
SIFI enters scientific collaboration with UCSF on Acanthamoeba Keratitis
Johnson & Johnson's nipocalimab granted FTD for treatment of Sjogren's disease
Vascarta launches phase I VAS101 clinical study in osteoarthritis
GRIN Therapeutics' Radiprodil receives Orphan Drug designation
Evommune enrols first patient in EVO301 Phase 2 trial
BioArctic receives US FDA orphan drug designation OOPD for exidavnemab